logo
Plus   Neg
Share
Email

Dr. Reddy's Laboratories Launches Fosaprepitant For Injection In U.S. Market

Pharmaceutical company Dr. Reddy's Laboratories Ltd. (RDY) announced Wednesday the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA). It is among the first generics to launch this product.

The EMEND for Injection brand had an U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.

Dr. Reddy's Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google CEO Sundar Pichai announced Monday a $10 billion Google for India Digitization Fund to help accelerate India's digital economy. The investment is planned over the next five to seven years through equity investments, partnerships, and operational, infrastructure and ecosystem investments. Logistics solutions provider Hi-Crush Inc. (HCR) announced Monday that it has voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. Hi-Crush has also entered into a Restructuring Support Agreement... Analog Devices, Inc. (ADI) and Maxim Integrated Products, Inc. (MXIM) announced Monday that they have entered into a definitive agreement under which ADI will acquire Maxim in an all stock transaction that values the combined enterprise at over $68 billion. The transaction, which was unanimously approved...
Follow RTT